Tirzepatide associated with lower dementia risk than semaglutide or SGLT2 inhibitors

A new observational study found that adults with type 2 diabetes who took tirzepatide had a lower risk of being diagnosed with dementia within two years than those who took semaglutide or an SGLT2 inhibitor, a different class of diabetes drug ^[1][2]. The study's authors stress the results are "hypothesis generating" and need to be confirmed in randomized controlled trials before anyone draws firm conclusions ^[1][2].

The research used real-world health records from the TriNetX global database and applied a method called target trial emulation, which tries to mimic a randomized trial using existing patient data ^[1][2]. Researchers built three separate comparisons among adults with type 2 diabetes who did not have dementia at the start of follow-up: tirzepatide versus SGLT2 inhibitors, semaglutide versus SGLT2 inhibitors, and tirzepatide versus semaglutide ^[2]. After statistically matching patients so the groups looked similar, the tirzepatide-versus-SGLT2-inhibitor comparison included 14,462 people, the semaglutide-versus-SGLT2-inhibitor comparison included 57,959 people, and the tirzepatide-versus-semaglutide comparison included 12,246 people ^[2].

Over two years, tirzepatide was linked to a 31 percent lower relative risk of a new dementia diagnosis compared with semaglutide, a hazard ratio of 0.69 with a 95 percent confidence interval of 0.48 to 0.99 ^[2]. Compared with SGLT2 inhibitors, tirzepatide was linked to a 34 percent lower relative risk of dementia, a hazard ratio of 0.66 with a confidence interval of 0.47 to 0.93 ^[2]. Tirzepatide was also associated with lower death rates in these comparisons, with hazard ratios of 0.72 and 0.29 in the reported analyses ^[2]. Separately, both tirzepatide and semaglutide were linked to fewer major adverse cardiovascular events than SGLT2 inhibitors ^[2]. To check whether the drug comparisons were picking up a real signal rather than some hidden bias, the researchers used Bell's palsy, a condition with no known link to these drugs, as a "falsification" test, according to the study summary.

Why it matters for patients

These numbers describe a difference between groups of patients on different medications, not a guarantee for any one person. The study cannot say why tirzepatide showed a lower dementia rate than semaglutide or SGLT2 inhibitors, and the authors themselves warn that residual confounding remains plausible, meaning some unmeasured difference between the groups of patients, rather than the drug itself, could explain part or all of the pattern ^[1][2].

This is a retrospective look at existing medical records, not a randomized clinical trial where patients are assigned by chance to different treatments. That design makes it easier for other health or lifestyle factors to sneak into the comparison and skew the result. The researchers themselves call the findings hypothesis generating, which in research terms means the study raises a question worth testing further rather than answering it ^[1][2]. People weighing treatment options for type 2 diabetes may see this study cited as one more data point about dementia risk, but it sits alongside existing evidence that GLP-1 drugs and SGLT2 inhibitors may already be linked to lower dementia risk in general, a background the authors note before describing tirzepatide's apparent edge ^[2].

What happens next

The study was published in Diabetes Research and Clinical Practice, with an online version dated May 2026 and available now ^[1][2]. The authors call for confirmation in randomized controlled trials, which would take considerably longer to design, run, and report than this database analysis. No trial timeline or sponsor has been announced in the sources reviewed for this story.